(R)-3-Cyclopentyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanenitrile

We are (R)-3-Cyclopentyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanenitrile CAS:1146629-84-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(R)-3-Cyclopentyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanenitrile
CAS.NO:1146629-84-6
Synonyms:(R)-3-Cyclopentyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanenitrile
(3R)-3-cyclopentyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]propanenitrile
(3R)-3-Cyclopentyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]propanenitrile
 
Physical and Chemical Properties:
Density 1.1±0.1 g/cm3
Boiling Point 471.8±25.0 °C at 760 mmHg
Molecular Formula C17H26BN3O2
Molecular Weight 315.218
Flash Point 239.1±23.2 °C
Vapour Pressure 0.0±1.2 mmHg at 25°C
Index of Refraction 1.561
 
Specification:
Appearance:White powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Ruxolitinib(CAS:941678-49-5).

(R)-3-Cyclopentyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanenitrile


Related News: Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.(R, E) -etil 5 – ([1,1'-bifenil] -4-il) -4 – ((terc-butoxicarbonil) amino) -2-metilpent-2-enoato CAS:149709-59-1 We partner with life science companies of all sizes, drawing on over 20 years of industry experience.pyrogallol At the same time, due to the increase in production costs and environmental protection cost pressures in Europe and the United States, as well as the improvement of process technology, production quality, and registration and certification capabilities of China’s bulk drug manufacturers, bulk drug companies have accelerated their transfer to China, and the bulk drug industry in China has produced Scale continues to increase.4-Chlorobenzo[d]thiazol-2(3H)-one Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.The monthly injection to suppress the virus that causes AIDS was aimed as an alternative to daily pills.

Related Products
Product Name
isonicotinic acid View Details
6-Bromo-5-chloropyridin-2-amine View Details
2-Fluoro-4-iodobenzonitrile View Details
N2-phenylacetyl-L-glutamine manufacturer 5-Fluoro-2-methylphenol manufacturer phloroglucinol manufacturer Bromoethane manufacturer 9-(2-naphthalenyl)-3,6-Dibromo-9H-carbazole manufacturer